spec sheet6 rows
Biotinoyl GHK, sold as Biotinoyl Tripeptide-1, is the copper peptide GHK with a biotin group attached to its N-terminus. It reaches consumers almost entirely inside Procapil, a three-part hair blend. ⚠️ Two things make it much weaker than its reputation. The biotin caps the exact chemical site GHK uses to carry copper, so it cannot work the way GHK-Cu is supposed to. And the whole of PubMed holds three papers on biotinylated GHK, none of which measures a single target.
- Accelerated wound healing in rats when incorporated into a collagen matrix
- Well tolerated; a cosmetic ingredient used at parts-per-million levels
- Mild local irritation in combination products
Mechanism
The molecule is glycyl-histidyl-lysine, the same tripeptide as GHK, with biotin joined by an amide bond to the alpha-amine of the N-terminal glycine.
⚠️ That single bond is the problem, and it is almost never mentioned. GHK's copper chemistry runs through the ATCUN motif, a copper-binding arrangement that requires a FREE N-terminal alpha-amine together with a histidine in the third position. Capping the amine with biotin removes half of what the motif needs. The point is made directly, if indirectly, by a later group who attached biotin to the C-terminal carboxyl instead and explained that they did so because such a strategy preserves the copper-binding ability of the GHK sequence.
Beyond that, there is very little to describe. ⚠️ No binding constant, inhibition constant or half-maximal concentration has ever been published for this compound at any target, and it has no entry in the main bioactivity database. Everything asserted about its mechanism is extrapolated from GHK and GHK-Cu, a it is chemically prevented from imitating at the copper site.
The two primary studies that do exist used it incorporated into a collagen matrix as a wound dressing in rats, where it bound the matrix better than a comparator and raised copper concentration at the wound about ninefold [1], and where it accelerated healing in diabetic rats [2]. Both came from a single laboratory and neither has been replicated.
Evidencehow good the literature is
The evidence is thin in a way worth stating precisely rather than summarising kindly.
A PubMed search for biotinylated GHK returns three papers in total, and one for Biotinoyl Tripeptide-1 returns none. There are no bioactivity records for it in the main pharmacology database, and no trial anywhere names it, biotinyl-GHK or Procapil as an intervention.
⚠️ One of those three papers should not be cited for this compound at all. It studies a biotinyl hydrazide attached to GHK's C-terminal carboxyl, with a reported mass around 580 against 566.7 for Biotinoyl Tripeptide-1: a different regiochemistry and a different molecule. Marketing copy and automated summaries conflate the two routinely.
Every human dataset is of a mixture. A comparison of platelet-rich plasma with and without topical Procapil favoured the combination on dermatologist and patient scales, but was quasi-experimental with subjective endpoints only [4]. A second trial comparing Procapil against a different blend, both with platelet-rich plasma, actually favoured the NON-Procapil arm [5]. Larger studies of multi-ingredient products are single-arm, open-label or brand-authored.
⚠️ The foundational Procapil study quoted everywhere, 35 men over four months with 67 percent improving, appears in a review's text but not in that review's reference list, and is almost certainly a manufacturer technical file rather than a published paper [3]. It could not be verified at source.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
No compound-specific toxicology has been published. It has been assessed only as part of an ingredient group in a cosmetic-industry safety review, with no systemic exposure data of its own. The two rat studies reported no adverse findings, but they were efficacy studies with no toxicology arm [1][2].
In practice the exposure is very small. Reviewed concentrations of use run from 0.00002 percent in shampoos to 0.0006 percent in leave-on hair products, which is a few parts per million in the bottle before any loss at the skin barrier. At that scale a topical peptide is unlikely to cause harm, and equally unlikely to reach a cell at a concentration where anything measured in a laboratory would occur.
Reported reactions in the combination trials were limited to mild local irritation.
History
GHK was identified in human plasma in the 1970s and became well known as a copper-carrying peptide with genuine wound-healing activity, which made it attractive to the cosmetic industry. Biotinylation was originally a laboratory convenience, a way to tag the peptide or anchor it to a matrix, and the two rat wound studies of the 2000s used it exactly that way. Its commercial life began when Sederma built it into Procapil alongside apigenin and oleanolic acid and marketed the blend for hair anchoring and follicle survival. Because the blend performed reasonably, the peptide inherited a reputation the blend earned, and the parts of that reputation involving copper delivery and androgen blockade belong respectively to a chemistry it cannot perform and to a different ingredient in the same bottle.
Subjective profileweighing the evidence above
A well-defined molecule that is not well characterised biologically, and that is a conclusion from evidence rather than a gap in searching. Three papers exist in the whole of PubMed, none measuring a target, and no trial has ever tested it on its own. The copper story it trades on is chemically blocked by its own biotin group. The reviewed cosmetic use levels are between 0.00002 and 0.0006 percent, which is a few parts per million, while every laboratory effect reported for GHK needs micromolar concentrations at the cell. Harmless, well-formulated, and asked to carry far more than the evidence supports.
Resources
This entry is here for reference.
Research
- 2005first citedBiotinylated GHK peptide incorporated collagenous matrix: a novel biomaterial for dermal wound…
- 2023controlled trialA Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redens…
- 2025most recentTopical alternatives for hair loss: beyond the conventional
- 1.Biotinylated GHK peptide incorporated collagenous matrix: a novel biomaterial for dermal wound healing in rats
- 2.A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices
- 3.Topical alternatives for hair loss: beyond the conventional
- 4.COMPARISON OF PLATELET RICH THERAPY ALONE WITH PLATELET RICH THERAPY ALONG WITH DAILY TOPICAL 5% PROCAPIL APPLICATION FOR THE TREATMENT OF ANDROGENETIC ALOPECIA.
- 5.A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl, Saw Palmetto, and Biotin With Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia.
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
Limitations of the evidence
- Its N-terminal biotin caps the ATCUN motif GHK uses to bind copper, so it cannot act as a copper peptide
- No binding or potency value has ever been published for it at any target
- Three papers exist in the whole of PubMed, and one of them is about a different regiochemistry entirely
- No trial has ever tested it alone; every human dataset is of a blend
- The DHT and 5-alpha-reductase action credited to it belongs to oleanolic acid, a different ingredient in Procapil
Adverse effects
- Mild local irritation in combination products